UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001012
Receipt number R000001177
Scientific Title A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01)
Date of disclosure of the study information 2008/02/04
Last modified on 2022/08/30 17:32:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01)

Acronym

A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01)

Scientific Title

A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01)

Scientific Title:Acronym

A randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor (JCOG0705/KGCA01)

Region

Japan Asia(except Japan)


Condition

Condition

clinical stage IV gastric cancer

Classification by specialty

Gastroenterology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the survival benefit and safety of gastrectomy plus chemotherapy compared to chemotherapy alone in clinical stage IV gastric cancer with a single non-curable factor

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

overall survival

Key secondary outcomes

progression-free survival, adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

A: Chemotherapy alone (S-1 80mg/m2 on days 1-21; CDDP 60mg/m2 on day 8, every 5 weeks)

Interventions/Control_2

B: Gastrectomy with D1 lymphadenectomy followed by chemotherapy (S-1 80mg/m2 on days 1-21; CDDP 60mg/m2 on day 8, every 5 weeks)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Histologically proven primary gastric adenocarcinoma.
2) Presence of distant metastases confined to either liver (H1), peritoneum (P1), or para-aortic lymphnode (16a1/b2), which is confirmed by both CT scan and laparotomy.
3) Clinical T1-3.
4) No other distant metastasis than H1, P1or M1(LN 16a1/b2).
5) No apparent pleural effusion.
6) Length of esophageal invasion 3cm or less with no need of thoracotomy for resection.
7) Aged 20 to 75 years old.
8) PS of 0 or 1.
9) Sufficient oral intake without active bleeding from the gastric tumor.
10) No prior treatment of chemotherapy or radiation therapy against any other malignancies, and no prior treatment for gastric cancer except EMR.
11) Adequate organ functions defined as indicated below
(1)WBC >= 3,000 /mm3 , WBC <= 12,000 /mm3
(2)Hb >= 8.0 g/dL without any transfusion 2 weeks before enrollment
(3)Plt >= 100,000 /mm3
(4)AST <= 100 IU/L
(5)ALT <= 100 IU/L
(6)T.Bil <= 2.0 mg/dL
(7)Cr <= 1.2 mg/dL
(8)Ccr >= 60 mL/min/body
12) Written informed consent

Key exclusion criteria

1) Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment.
2) Women during pregnancy or breast-feeding.
3) Psychosis.
4) Systemic steroids medication.
5) Medication of furucytocin, fenytoin, or warfarin.
6) Active bacterial infection or mycosis, affecting systemic condition.
7) Myocardial infarction or unstable angina, occurred within 6 months.
8) Uncontrollable hypertension.
9) Uncontrollable diabetes mellitus or administration of insulin.
10) Pulmonary disease necessitating continuous oxygen supply.

Target sample size

330


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshimasa Tsujinaka

Organization

National Hospital Organization Osaka National Hospital

Division name

Department of Surgery

Zip code


Address

2-1-14, Hoenzaka, Chuo-ku, Osaka, Osaka 540-0006, Japan

TEL

06-6942-1331

Email

JCOG_sir@ml.jcog.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kazumasa Fujitani

Organization

JCOG0705 Coordinating Office

Division name

National Hospital Organization Osaka National Hospital, Department of Surgery

Zip code


Address

2-1-14, Hoenzaka, Chuo-ku, Osaka, Osaka 540-0006, Japan

TEL

06-6942-1331

Homepage URL

http://www.jcog.jp/

Email

JCOG_sir@ml.jcog.jp


Sponsor or person

Institute

Japan Clinical Oncology Group (JCOG)

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

函館厚生院函館五稜郭病院(北海道)
岩手医科大学 (岩手県)
国立病院機構仙台医療センター(宮城県)
宮城県立がんセンター (宮城県)
山形県立中央病院 (山形県)
栃木県立がんセンター(栃木県)
防衛医科大学校 (埼玉県)
埼玉県立がんセンター(埼玉県)
国立がん研究センター東病院(千葉県)
国立がん研究センター中央病院 (東京都)
がん・感染症センター都立駒込病院 (東京都)
東京医科歯科大学 (東京都)
がん研究会有明病院 (東京都)
虎の門病院(東京都)
都立墨東病院 (東京都)
神奈川県立病院機構神奈川県立がんセンター (神奈川県)
北里大学医学部(神奈川県)
横浜市立大学附属市民総合医療センター(神奈川県)
新潟県立がんセンター新潟病院 (新潟県)
新潟県厚生連長岡中央綜合病院 (新潟県)
燕労災病院 (新潟県)
富山県立中央病院 (富山県)
石川県立中央病院(石川県)
岐阜大学医学部(岐阜県)
岐阜市民病院 (岐阜県)
静岡県立総合病院 (静岡県)
静岡県立静岡がんセンター(静岡県)
愛知県がんセンター中央病院 (愛知県)
名古屋大学医学部(愛知県)
藤田保健衛生大学 (愛知県)
国立病院機構京都医療センター(京都府)
京都第2赤十字病院 (京都府)
大阪大学医学部(大阪府)
近畿大学医学部 (大阪府)
大阪府立病院機構大阪府立成人病センター (大阪府)
国立病院機構大阪医療センター (大阪府)
大阪医科大学 (大阪府)
市立豊中病院 (大阪府)
市立堺病院 (大阪府)
関西医科大学附属枚方病院(大阪府)
神戸大学医学部(兵庫県)
関西労災病院(兵庫県)
兵庫医科大学(兵庫県)
兵庫県立がんセンター(兵庫県)
市立伊丹病院 (兵庫県)
天理よろづ相談所病院(奈良県)
和歌山県立医科大学 (和歌山県)
島根大学医学部(島根県)
広島市立広島市民病院 (広島県)
広島市立安佐市民病院(広島県)
福山市民病院(広島県)
国立病院機構四国がんセンター(愛媛県)
高知医療センター(高知県)
大分大学医学部附属病院(大分県)


Other administrative information

Date of disclosure of the study information

2008 Year 02 Month 04 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://www.ncbi.nlm.nih.gov/pubmed/26822397

Number of participants that the trial has enrolled


Results

See the datails via "URL releasing results" above.
Also the details can be seen in the JCOG website:
http://www.jcog.jp/en/trials/index.html

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2007 Year 12 Month 18 Day

Date of IRB

2008 Year 02 Month 01 Day

Anticipated trial start date

2008 Year 02 Month 01 Day

Last follow-up date

2014 Year 02 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2008 Year 02 Month 04 Day

Last modified on

2022 Year 08 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001177


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name